Evolution of Telomerase Inhibitors: A Review on Key Patents from 2015 to 2023

IF 1.9 4区 化学 Q3 CHEMISTRY, MULTIDISCIPLINARY
Rajdeep Dey, Dr. Keerti Vishwakarma, Dr. Bhumika Patel, Dr. Vivek K. Vyas, Dr. Hardik Bhatt
{"title":"Evolution of Telomerase Inhibitors: A Review on Key Patents from 2015 to 2023","authors":"Rajdeep Dey,&nbsp;Dr. Keerti Vishwakarma,&nbsp;Dr. Bhumika Patel,&nbsp;Dr. Vivek K. Vyas,&nbsp;Dr. Hardik Bhatt","doi":"10.1002/slct.202404444","DOIUrl":null,"url":null,"abstract":"<p>Telomerase (TERT) is a ribonucleoprotein that regulates telomere length and maintains chromosomal integrity. TERT is a widely expressed protein for replicative immortality in most malignant tumours. TERT is a protein produced by cancer cells that prevents telomere shortening by adding telomere sequences beyond the Hayflick limit, allowing them to divide in an uncontrolled manner. Inhibition of the TERT enzyme is a recognised therapy for treating cancer. The basic objective of the review is to collectively represent the current scenario of treating cancer by inhibiting TERT. With a focus on the recently patented TERT inhibitors and clinical trial data released between 2015 and 2023, this review highlights the work relevant to the development of TERT inhibitors. Furthermore, recent advancements in the clinical development of TERT inhibitors, along with prospective new combinations, are also discussed. The use of TERT inhibitors in cancer therapy has been granted with great interest and significant attention by researchers along with a promising outcome in terms of therapeutic value. Several clinical trial applications and their data gave strong evidence of the use of TERT inhibitors for cancer therapy which provided target therapies, vaccine therapies, nucleoside, non-nucleoside therapies, and so forth with reduced side effects and enhanced potency.</p>","PeriodicalId":146,"journal":{"name":"ChemistrySelect","volume":"9 47","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemistrySelect","FirstCategoryId":"92","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/slct.202404444","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

Telomerase (TERT) is a ribonucleoprotein that regulates telomere length and maintains chromosomal integrity. TERT is a widely expressed protein for replicative immortality in most malignant tumours. TERT is a protein produced by cancer cells that prevents telomere shortening by adding telomere sequences beyond the Hayflick limit, allowing them to divide in an uncontrolled manner. Inhibition of the TERT enzyme is a recognised therapy for treating cancer. The basic objective of the review is to collectively represent the current scenario of treating cancer by inhibiting TERT. With a focus on the recently patented TERT inhibitors and clinical trial data released between 2015 and 2023, this review highlights the work relevant to the development of TERT inhibitors. Furthermore, recent advancements in the clinical development of TERT inhibitors, along with prospective new combinations, are also discussed. The use of TERT inhibitors in cancer therapy has been granted with great interest and significant attention by researchers along with a promising outcome in terms of therapeutic value. Several clinical trial applications and their data gave strong evidence of the use of TERT inhibitors for cancer therapy which provided target therapies, vaccine therapies, nucleoside, non-nucleoside therapies, and so forth with reduced side effects and enhanced potency.

Abstract Image

求助全文
约1分钟内获得全文 求助全文
来源期刊
ChemistrySelect
ChemistrySelect Chemistry-General Chemistry
CiteScore
3.30
自引率
4.80%
发文量
1809
审稿时长
1.6 months
期刊介绍: ChemistrySelect is the latest journal from ChemPubSoc Europe and Wiley-VCH. It offers researchers a quality society-owned journal in which to publish their work in all areas of chemistry. Manuscripts are evaluated by active researchers to ensure they add meaningfully to the scientific literature, and those accepted are processed quickly to ensure rapid online publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信